Naomi Nagura1,2, Naoki Hayashi1, Junko Takei1, Atsushi Yoshida1, Tomohiro Ochi1, Yoshiko Iwahira2, Hideko Yamauchi3. 1. Department of Breast Surgical Oncology, St. Luke'S International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. 2. Breast Surgery Clinic, YCC Takanawa Bild., 2,3/F Takanawa, Minato-ku, Tokyo, 108-0074, Japan. 3. Department of Breast Surgical Oncology, St. Luke'S International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. hideyama@luke.ac.jp.
Abstract
BACKGROUND: Breast reconstruction is a favorable option for women with BRCA1 or BRCA2 mutations (BRCA1/2Mut+) who undergo risk-reducing mastectomy (RRM). We assessed characteristics of patients who underwent RRM, with or without breast reconstruction. METHODS: We included 46 patients with BRCA1/2Mut+ who underwent RRM from July 2011 to December 2017. RESULTS: Among the 46 patients who underwent RRM, 3 had not been diagnosed with breast cancer (BC) and 43 had cancer in a single breast; 33 patients (71.7%) underwent breast reconstruction with RRM; and 13 patients (28.3%) did not undergo breast reconstruction. All of 3 patients who had not been diagnosed with BC underwent bilateral RRM with breast reconstruction. There was no significant difference of clinical characteristic between patients undergoing RRM with and without breast reconstruction. However, patients who decided to undergo RRM with the current diagnosis of BC had significantly higher rates of RRM with breast reconstruction than that of patients with a past history of BC (P = 0.043). The rate of nipple-sparing mastectomy (NSM) in patients with breast reconstruction was significantly higher (28 of the 37 breasts, 75.7%) than that in patients without reconstruction (3 of the 14 breasts, 21.4%) (P < 0.001). Two patients who had complications underwent RRM with breast reconstruction, and one of them had a history of irradiation after lumpectomy. CONCLUSIONS: For BRCA1/2Mut+ patients, the decision of taking RRM with the diagnosis of current BC might affect whether they undergo immediate breast reconstruction with RRM. These patients who undergo RRM with breast reconstruction preferred NSM to skin-sparing mastectomies.
BACKGROUND: Breast reconstruction is a favorable option for women with BRCA1 or BRCA2 mutations (BRCA1/2Mut+) who undergo risk-reducing mastectomy (RRM). We assessed characteristics of patients who underwent RRM, with or without breast reconstruction. METHODS: We included 46 patients with BRCA1/2Mut+ who underwent RRM from July 2011 to December 2017. RESULTS: Among the 46 patients who underwent RRM, 3 had not been diagnosed with breast cancer (BC) and 43 had cancer in a single breast; 33 patients (71.7%) underwent breast reconstruction with RRM; and 13 patients (28.3%) did not undergo breast reconstruction. All of 3 patients who had not been diagnosed with BC underwent bilateral RRM with breast reconstruction. There was no significant difference of clinical characteristic between patients undergoing RRM with and without breast reconstruction. However, patients who decided to undergo RRM with the current diagnosis of BC had significantly higher rates of RRM with breast reconstruction than that of patients with a past history of BC (P = 0.043). The rate of nipple-sparing mastectomy (NSM) in patients with breast reconstruction was significantly higher (28 of the 37 breasts, 75.7%) than that in patients without reconstruction (3 of the 14 breasts, 21.4%) (P < 0.001). Two patients who had complications underwent RRM with breast reconstruction, and one of them had a history of irradiation after lumpectomy. CONCLUSIONS: For BRCA1/2Mut+patients, the decision of taking RRM with the diagnosis of current BC might affect whether they undergo immediate breast reconstruction with RRM. These patients who undergo RRM with breast reconstruction preferred NSM to skin-sparing mastectomies.
Entities:
Keywords:
BRCA mutation carriers; Breast cancer; Breast reconstruction; Risk-reducing mastectomy
Authors: Bernadette A M Heemskerk-Gerritsen; Matti A Rookus; Cora M Aalfs; Margreet G E M Ausems; Johanna M Collée; Liesbeth Jansen; C Marleen Kets; Kristien B M I Keymeulen; Linetta B Koppert; Hanne E J Meijers-Heijboer; Thea M Mooij; Rob A E M Tollenaar; Hans F A Vasen; Maartje J Hooning; Caroline Seynaeve Journal: Int J Cancer Date: 2014-07-08 Impact factor: 7.396
Authors: Vivian J Hu; Sean P McCleary; Carolyn P Smullin; Ricardo Rosales Morales; Andrew L Da Lio Journal: Plast Reconstr Surg Glob Open Date: 2022-04-18
Authors: Adelina Plangger; Werner Haslik; Barbara Rath; Christoph Neumayer; Gerhard Hamilton Journal: J Mammary Gland Biol Neoplasia Date: 2021-07-06 Impact factor: 2.673